Medication company Viatris (NASDAQ: VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know.
Viatris beat analysts’ revenue expectations by 4.2% last quarter, reporting revenues of $3.58 billion, down 5.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
Is Viatris a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Viatris’s revenue to decline 3.9% year on year to $3.61 billion, in line with the 4.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.62 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Viatris has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Viatris’s peers in the pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 11.7%, beating analysts’ expectations by 2.1%, and Eli Lilly reported revenues up 53.9%, topping estimates by 9.6%. Amneal traded up 3.7% following the results while Eli Lilly was also up 6%.
Read our full analysis of Amneal’s results here and Eli Lilly’s results here.
Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. Viatris is up 4.1% during the same time and is heading into earnings with an average analyst price target of $12 (compared to the current share price of $10.55).
P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
